1.Treatment of Compensatory Gustatory Hyperhidrosis with Topical Glycopyrrolate.
Won Oak KIM ; Hae Keum KIL ; Duck Me YOON ; Min Jeong CHO
Yonsei Medical Journal 2003;44(4):579-582
Gustatory hyperhidrosis is facial sweating usually associated with the eating of hot spicy food or even smelling this food. Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or aluminum chloride, and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embrasssed whilst eating hot spicy foods. Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate). The topical application of a glycopyrrolate pad appeared to be safe, efficacious, well tolerated, and a convenient method of treatment for moderate to severe symptoms of gustatory hyperhidrosis in post transthoracic endoscopic sympathectomy or sympathicotomy patients, with few side effects.
Administration, Topical
;
Adolescent
;
Adult
;
Cholinergic Antagonists/*administration & dosage
;
Endoscopy/adverse effects
;
Female
;
Glycopyrrolate/*administration & dosage
;
Human
;
Male
;
Sweating, Gustatory/*drug therapy/etiology
;
Sympathectomy/adverse effects/methods
2.Neuroprotective effect of the ethanol extract of Artemisia capillaris on transient forebrain ischemia in mice via nicotinic cholinergic receptor.
Huiyoung KWON ; Ji Wook JUNG ; Young Choon LEE ; Jong Hoon RYU ; Dong Hyun KIM
Chinese Journal of Natural Medicines (English Ed.) 2018;16(6):428-435
Artemisia capillaris Thunberg is a medicinal plant used as a traditional medicine in many cultures. It is an effective remedy for liver problems including hepatitis. Recent pharmacological reports have indicated that Artemisia species can exert various neurological effects. Previously, we reported a memory-enhancing effect of Artemisia species. However, the mechanisms underlying the neuroprotective effect of A. capillaris (AC) are still unknown. In the present study, we investigated the effect of an ethanol extract of AC on ischemic brain injury in a mouse model of transient forebrain ischemia. The mice were treated with AC for seven days, beginning one day before induction of transient forebrain ischemia. Behavioral deficits were investigated using the Y-maze. Nissl and Fluoro-jade B staining were used to indicate the site of injury. To determine the underlying mechanisms for the drug, we measured acetylcholinesterase activity. AC (200 mg·kg) treatment reduced transient forebrain ischemia-induced neuronal cell death in the hippocampal CA1 region. The AC-treated group also showed significant amelioration in the spontaneous alternation of the Y-maze test performance, compared to that in the untreated transient forebrain ischemia group. Moreover, AC treatment showed a concentration-dependent inhibitory effect on acetylcholinesterase activity in vitro. Finally, the effect of AC on forebrain ischemia was blocked by mecamylamine, a nonselective nicotinic acetylcholine receptor antagonist. Our results suggested that in a model of forebrain ischemia, AC protected against neuronal death through the activation of nicotinic acetylcholine receptors.
Acetylcholinesterase
;
metabolism
;
Animals
;
Artemisia
;
Cell Death
;
drug effects
;
Cholinergic Antagonists
;
pharmacology
;
Disease Models, Animal
;
Ethanol
;
chemistry
;
Hippocampus
;
pathology
;
physiopathology
;
Ischemic Attack, Transient
;
drug therapy
;
pathology
;
physiopathology
;
Male
;
Mecamylamine
;
pharmacology
;
Memory
;
drug effects
;
Mice
;
Mice, Inbred C57BL
;
Models, Neurological
;
Neuroprotective Agents
;
administration & dosage
;
pharmacology
;
Phytotherapy
;
Plant Components, Aerial
;
chemistry
;
Plant Extracts
;
administration & dosage
;
pharmacology
;
Receptors, Cholinergic
;
metabolism
3.Effect of scopolamine on depression in mice.
Acta Pharmaceutica Sinica 2011;46(4):400-405
Based on the report of previous clinical study which showed cholinergic receptor antagonist scopolamine had antidepressant activity, this study was to investigate the antidepressant activity of scopolamine and explore its effective dose in mice, and to evaluate the effect of scopolamine on the central nervous system and learning/memory ability at its antidepressant effective dose. Tail suspension test, forced swimming test, step-down passive avoidance test and open field test were used to evaluate its effects on mice. Compared with the vehicle control group, single-dose administration of scopolamine (0.1-0.4 mg x kg(-1), ip) significantly decreased the immobility time (P < 0.01 or P < 0.001) in tail suspension test, and significantly decreased the immobility time (P < 0.001) in forced swimming test, but had no effect on the step-down latency and errors in step-down passive avoidance test. Scopolamine (0.1 and 0.2 mg x kg(-1), ip) had no influence on the locomotor activity in open field test, while at dose of 0.4 mg x kg(-1) significantly increase the locomotor activity. These results showed that scopolamine produced reliable antidepressant effect at doses of 0.1 and 0.2 mg x kg(-1), without impairment on learning and memory, as well as excitory or inhibitory effect on central nervous system in mice.
Animals
;
Antidepressive Agents
;
administration & dosage
;
pharmacology
;
Avoidance Learning
;
drug effects
;
Behavior, Animal
;
drug effects
;
Cholinergic Antagonists
;
administration & dosage
;
pharmacology
;
Depression
;
physiopathology
;
prevention & control
;
Hindlimb Suspension
;
Male
;
Memory
;
drug effects
;
Mice
;
Mice, Inbred ICR
;
Motor Activity
;
drug effects
;
Random Allocation
;
Scopolamine Hydrobromide
;
administration & dosage
;
pharmacology
;
Swimming
4.Prevalence and risk factors for reflux esophagitis in patients with chronic obstructive pulmonary disease.
Seo Woo KIM ; Jin Hwa LEE ; Yun Su SIM ; Yon Ju RYU ; Jung Hyun CHANG
The Korean Journal of Internal Medicine 2014;29(4):466-473
BACKGROUND/AIMS: Gastroesophageal reflux disease is one of the most common causes of chronic cough and is a potential risk factor for the exacerbation of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the prevalence and risk factors for reflux esophagitis (RE) in COPD patients. METHODS: From our hospital database, between September 2006 and April 2010, we searched for subjects who were 40 years old or older and had undergone both postbronchodilator spirometry and esophagogastroduodenoscopy (EGD). COPD was defined as having a ratio of forced expiratory volume in 1 second to forced vital capacity < 0.7 in postbronchodilator spirometry and no abnormality causing airway obstruction, except emphysematous changes, on a chest X-ray. The diagnosis of RE was based on a mucosal break surrounding the distal esophageal sphincter through EGD. RESULTS: In total, 253 patients with COPD were enrolled. The prevalence of RE in COPD was 30% (76/253). Multiple logistic regression analyses revealed that age (odds ratio [OR], 0.950; 95% confidence interval [CI], 0.918 to 0.983; p = 0.003), smoking pack-years (OR, 1.015; 95% CI, 1.004 to 1.025; p = 0.006), and inhaled anticholinergics (OR, 0.516; 95% CI, 0.271 to 0.982; p = 0.044) were independently associated with RE in COPD patients. CONCLUSIONS: The prevalence of RE in our COPD patients was higher than that reported previously in the Korean general population. In COPD, smoking increased the risk of RE, whereas inhaled anticholinergics may be associated with a reduced risk of RE.
Administration, Inhalation
;
Aged
;
Chi-Square Distribution
;
Cholinergic Antagonists/administration & dosage
;
Comorbidity
;
Databases, Factual
;
Endoscopy, Gastrointestinal
;
Esophagitis, Peptic/diagnosis/*epidemiology
;
Female
;
Humans
;
Logistic Models
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Odds Ratio
;
Prevalence
;
Protective Factors
;
Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/*epidemiology
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Smoking/adverse effects/epidemiology
;
Spirometry
5.Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Yan TANG ; Dan MASSEY ; Nan-shan ZHONG
Chinese Medical Journal 2013;126(19):3603-3607
BACKGROUNDA pharmacokinetic study in an Asian population showed that tiotropium 5 µg via Respimat leads to the same plasma levels compared to 18 µg via HandiHaler. The objective of the trial was to compare the efficacy and safety of longterm treatment (1 year) with tiotropium bromide (5 µg) via Respimat® with placebo in patients with chronic obstructive pulmonary disease (COPD).
METHODSA total of 3991 patients were randomized in this double-blind, placebo controlled, parallel group study, while in China 338 patients (309 males, 29 females) received either tiotropium bromide (n = 167) or placebo (n = 171). Tiotropium bromide solution or matching placebo was delivered via Respimat® at a dosage of 5 µg (2×2.5 µg/puff) once daily for 48 weeks. Co-primary endpoints were trough forced expiratory volume in one second (FEV1) and the time to first exacerbation.
RESULTSStatistically significant improvements in trough FEV1 and trough forced vital capacity (FVC) in the tiotropium group were achieved at weeks 4, 24, and 48 compared with those in the placebo group. A statistically significant difference (P = 0.0027) in favour of tiotropium was also observed for the time to first exacerbation. The total numbers of exacerbations during treatment were 90 and 128 in the tiotropium and placebo groups, respectively, with a rate ratio of 0.69 (P = 0.0164). The difference between the treatment groups in the adjusted mean changes from baseline of St. George Respiratory Questionnaire (SGRQ) total score was -3.9 (95% CI: -7.5, -0.2) and was of statistical significance (P = 0.0367). The incidences of serious adverse events (SAEs) in the tiotropium and placebo groups were 16.2% and 17.0%, respectively. Seven deaths occurred whilst patients were on treatment, four in the tiotropium group and three in the placebo group, all of which were assessed as non-related study drugs by the investigators.
CONCLUSIONSTiotropium significantly improved lung function and quality of life, delayed the time to first exacerbation, reduced the number of exacerbations. Overall, tiotropium was well tolerated.
Administration, Inhalation ; Aged ; Bronchodilator Agents ; adverse effects ; therapeutic use ; Cholinergic Antagonists ; adverse effects ; therapeutic use ; Double-Blind Method ; Female ; Forced Expiratory Volume ; Humans ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive ; drug therapy ; physiopathology ; Scopolamine Derivatives ; adverse effects ; therapeutic use ; Tiotropium Bromide